RU2014132706A - Нуклеиновые кислоты, специфически связывающие cgrp - Google Patents

Нуклеиновые кислоты, специфически связывающие cgrp Download PDF

Info

Publication number
RU2014132706A
RU2014132706A RU2014132706A RU2014132706A RU2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A RU 2014132706 A RU2014132706 A RU 2014132706A
Authority
RU
Russia
Prior art keywords
nucleic acid
seq
acid molecule
molecule according
cgrp
Prior art date
Application number
RU2014132706A
Other languages
English (en)
Russian (ru)
Inventor
Зимоне ШУЛЬЦХЕН
Вернер ПУРШКЕ
Флориан Ярош
Кай ХЕЛИГ
Кристиан Мааш
Свен Клуссманн
Original Assignee
Ноксон Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Ноксон Фарма Аг filed Critical Ноксон Фарма Аг
Publication of RU2014132706A publication Critical patent/RU2014132706A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014132706A 2012-01-10 2013-01-10 Нуклеиновые кислоты, специфически связывающие cgrp RU2014132706A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12000105 2012-01-10
EPPCT/EP2012/000089 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12000105.2 2012-01-10
PCT/EP2013/000055 WO2013104539A1 (en) 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp

Publications (1)

Publication Number Publication Date
RU2014132706A true RU2014132706A (ru) 2016-02-27

Family

ID=48781062

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014132706A RU2014132706A (ru) 2012-01-10 2013-01-10 Нуклеиновые кислоты, специфически связывающие cgrp

Country Status (14)

Country Link
US (1) US9163243B2 (https=)
EP (1) EP2802659A1 (https=)
JP (1) JP2015506174A (https=)
KR (1) KR20140111704A (https=)
CN (1) CN104136612A (https=)
AU (1) AU2013209130A1 (https=)
BR (1) BR112014016939A2 (https=)
CA (1) CA2860809A1 (https=)
HK (1) HK1198370A1 (https=)
IL (1) IL233515A0 (https=)
MX (1) MX2014008456A (https=)
RU (1) RU2014132706A (https=)
SG (1) SG11201403769YA (https=)
WO (1) WO2013104539A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2815444C2 (ru) * 2018-11-12 2024-03-15 Аптарион Биотех Аг Cxcl8-связывающие нуклеиновые кислоты

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104540A1 (en) 2012-01-10 2013-07-18 Noxxon Pharma Ag New c5a binding nucleic acids
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
JP6584868B2 (ja) * 2015-02-25 2019-10-02 学校法人 関西大学 ゲル素材及びその製造方法
EA201890578A1 (ru) * 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
KR102929968B1 (ko) * 2018-11-12 2026-02-25 아프타리온 바이오테크 아게 Cxcl8 결합 핵산

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
AU732820B2 (en) 1995-06-02 2001-05-03 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
DE69433747D1 (de) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
RU2180311C1 (ru) 2001-07-05 2002-03-10 Мешалкин Георгий Алексеевич Защитная пробка
US7629456B2 (en) 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US7879991B2 (en) * 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
MXPA05011022A (es) 2003-04-13 2006-04-27 Enzon Pharmaceuticals Inc Profarmacos oligonucleotidos polimericos.
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20090281296A1 (en) 2004-02-09 2009-11-12 Supramol Parenteral Colloid Gmbh Process for the production of conjugates from polysaccharides and polynucelotides
MXPA06010782A (es) 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
CN101098703B (zh) 2004-11-05 2011-08-03 费城儿童医院 用于分子治疗的生物降解连接剂
EP1877069A2 (de) * 2005-05-04 2008-01-16 Noxxon Pharma AG Neue verwendung von spiegelmeren
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
WO2008052774A2 (en) 2006-10-31 2008-05-08 Noxxon Pharma Ag Methods for detection of a single- or double-stranded nucleic acid molecule
US8871920B2 (en) 2010-04-21 2014-10-28 Noxxon Pharma Ag Lipid binding nucleic acids
AU2012206750A1 (en) * 2011-01-10 2013-07-18 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2815444C2 (ru) * 2018-11-12 2024-03-15 Аптарион Биотех Аг Cxcl8-связывающие нуклеиновые кислоты

Also Published As

Publication number Publication date
KR20140111704A (ko) 2014-09-19
US9163243B2 (en) 2015-10-20
MX2014008456A (es) 2014-11-25
HK1198370A1 (en) 2015-04-10
IL233515A0 (en) 2014-08-31
BR112014016939A2 (pt) 2019-09-24
AU2013209130A1 (en) 2014-07-10
CA2860809A1 (en) 2013-07-18
EP2802659A1 (en) 2014-11-19
JP2015506174A (ja) 2015-03-02
SG11201403769YA (en) 2014-07-30
US20150031755A1 (en) 2015-01-29
CN104136612A (zh) 2014-11-05
WO2013104539A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
RU2014132706A (ru) Нуклеиновые кислоты, специфически связывающие cgrp
RU2014132708A (ru) НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ
DE69637430T2 (de) Neue opioid peptide, selektiv für kappa rezeptor
JP2015506174A5 (https=)
JP2013524792A5 (https=)
Suat et al. Design of β-turn based therapeutic agents
Bigoni et al. Nociceptin/orphanin FQ receptor ligands
Ung et al. Tripeptide motifs in biology: targets for peptidomimetic design
JP2015509705A5 (https=)
JP2014533098A5 (https=)
DE69212914T2 (de) Schnellsynthese und Screening von Peptidmimetika
RU2010116245A (ru) НУКЛЕИНОВЫЕ КИСЛОТЫ, СВЯЗЫВАЮЩИЕ C5a
CN1826353A (zh) 新的黑皮质素受体模板、肽及其用途
JP2010202653A (ja) 抗梗塞分子
Todorov et al. Synthesis, characterization and nociceptive screening of new VV-hemorphin-5 analogues
Romero et al. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective μ/κ antagonist in the [35S]‐GTP‐γ‐S functional binding assay
Li et al. Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin?
Sluka et al. Reagents and methods for the solid-phase synthesis of protein-EDTA for use in affinity cleaving
Ogawa et al. Synthesis and Structure− Activity Relationships of an Orally Available and Long-Acting Analgesic Peptide, N α-Amidino-Tyr-d-Arg-Phe-MeβAla-OH (ADAMB)
Harris et al. Antinociceptive activity of thiazole-containing cyclized DAMGO and Leu-(Met) enkephalin analogs
US7144986B2 (en) Polypeptides comprising IL-6 ligand binding receptor domains
CN118221772A (zh) 一种μ-芋螺毒素结构优化的突变体及其应用
EP2328925A1 (en) Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
EP0700928A1 (de) Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
CN104877005A (zh) 非天然氨基酸修饰的内吗啡肽-1类似物及其合成和应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170403